Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
Status unconfirmed
Conditions studied: COVID-19, SARS-CoV-2 Infection
In brief
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment. The purpose of this research is to aid in the testing effort by collecting samples from people who have been diagnosed with COVID-19 or are suspected of having COVID-19. Samples you provide will be used investigationally by INanoBio to develop a test to determine when antibodies against various SARS-CoV-2 proteins are detectable. Up to approximately 80 subjects of all ages with either a suspected or lab-confirmed diagnosis of COVID-19 will take part in this research.
Key facts
- Study ID
- NCT04465981
- Run by
- INanoBio Inc.
- People needed
- 80
- Starts
- 2020-07-03
- Expected to finish
- 2022-12-01
- Last updated by the study team
- 2021-08-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject must meet all of the following criteria to be eligible for treatment in the study:
- Subject or legal representative understands the nature of the procedure and has signed the Subject Informed Consent Form prior to study procedures
- For the COVID-19 Cohort
- Subject has lab-confirmed diagnosis of COVID-19 by RT-PCR
- For the PUI Cohort
- Subject has suspected COVID-19 according to medical evaluation, but does not yet have lab-confirmed diagnosis of COVID-19 (results outstanding, or has tested negative by RT-PCR)
You may not qualify if…
- Subject or legal representative not willing to consent
Where it is running
- TMC HealthCare — Tucson, Arizona, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.